Synonyms AHU-377 PubChem CID 9811834 ChemSpider 7987587 Formula C24H29NO5 | CAS Number 149709-62-6 DrugBank DB09292 Molar mass 411.49 g/mol | |
 | ||
ATC code C09DX04 (WHO) (combination with valsartan) | ||
Sacubitril (/səˈkjuːbᵻtrɪl/; INN) is an antihypertensive drug used in combination with valsartan. The combination drug valsartan/sacubitril, known during trials as LCZ696 and marketed under the brand name Entresto, is a treatment for heart failure. It was approved under the FDA's priority review process for use in heart failure on July 7, 2015.
Mechanism of action
Sacubitril is a prodrug that is activated to sacubitrilat (LBQ657) by de-ethylation via esterases. Sacubitrilat inhibits the enzyme neprilysin, which is responsible for the degradation of atrial and brain natriuretic peptide, two blood pressure-lowering peptides that work mainly by reducing blood volume. In addition, neprilysin degrades a variety of peptides including bradykinin, an inflammatory mediator exerting potent vasodilatory action.
